However, after entering the 21st century, with the approval of intravitreal injection of anti-VEGF medications by the US Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (AMD) in 2004 (Durand, 2017), the incidence of injection-related endophthalmitis, another mainstream manifestation, has gradually increased. This evidence concerns the gene VEGFA and endophthalmitis.